Terazol 3
(Terconazole)ApprovedSmall molecule
Terazol 3 is one of 40 small molecule programs targeting Vulvovaginal Candidiasis. It is currently in Approved.
2
Indications
6
Total Trials
0
Active Trials
39
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
48 competitors in Candidiasis
#DrugCompanyPhaseTrials
1Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Mycamine
BBaxter Healthcare Corporation
Approved
Cancidas
FFresenius Kabi Oncology Ltd.
Approved
Eraxis
VVicuron Pharmaceuticals
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Vfend
PPrism Pharmaceuticals
Approved
Lotrimin
BayerPhase 3
Ambisome
GileadApproved
Mycostatin
GGood Molecules, LLC
Phase 3
Nizoral
WWim Janssens
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Infections2 trials
Vulvovaginal Candidiasis2 trials
Candidiasis1 trial
Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis
Unknown status·—·Phase 3·NCT03473418·69 enrolled
Regulatory
FDA Approval Timeline[4]
Dec 31, 1987
TERAZOL 7
NDA NDA019579
May 24, 1988
TERAZOL 3
NDA NDA019641
Feb 21, 1991
TERAZOL 3
NDA NDA019964
Oct 1, 2004
TERCONAZOLE
NDA NDA021735
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Terconazole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- WWim Janssens